• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Mineralys Therapeutics (MLYS) Could Be 47% Undervalued Following Its Q2 Results Date

    Simply Wall St·08/06/2026 21:28:45
    Listen to the news

    Mineralys Therapeutics (MLYS) has set August 11, 2026 as the date to report its second quarter results. The company will hold a conference call and webcast that may refocus attention on its cardiorenal drug pipeline.

    See our latest analysis for Mineralys Therapeutics.

    At a share price of $26.99, Mineralys Therapeutics has seen short term pressure, with the 30 day share price return down 11.39% and the year to date share price return down 24.42%. However, the 1 year total shareholder return of 109.71% and 3 year total shareholder return of 105.72% point to stronger longer term momentum tied to shifting expectations around its cardiorenal pipeline and risk profile.

    If this kind of pipeline driven story interests you, it can be worth widening your research beyond a single stock using our healthcare focused screener for 42 healthcare AI stocks

    After a sharp pullback following very strong 1 year gains, Mineralys Therapeutics now sits at a very different entry point. Does the balance of cardiorenal upside and execution risk still favour new buyers, or not?

    Most Popular Narrative: 46.9% Undervalued

    Compared with the narrative fair value of $50.88, Mineralys Therapeutics at $26.99 sits at a steep discount that reflects both optimism about lorundrostat and meaningful execution risk around turning a single asset into a full cardiorenal franchise.

    Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.

    Read the complete narrative. Read the complete narrative.

    Want to see what sits under that potential shift from losses to a revenue story. The narrative leans heavily on rapid revenue build, improved margins and a rich future earnings multiple that is well above typical biotech expectations. Curious which assumptions really drive that gap between price and fair value.

    Result: Fair Value of $50.88 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the Mineralys Therapeutics story still hinges on successful lorundrostat approval and uptake, with regulatory setbacks or slower than expected prescribing both capable of undermining this upside case.

    Find out about the key risks to this Mineralys Therapeutics narrative.

    Next Steps

    The mix of upside potential and real risks around Mineralys Therapeutics is clear. If you want to move quickly and form your own view, start by weighing the 2 key rewards and 4 important warning signs

    Looking for more investment ideas beyond Mineralys Therapeutics?

    If you want broader context around Mineralys Therapeutics, use these focused stock ideas to pressure test your thinking and avoid missing opportunities that fit your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.